Interferon-α after autologous stem cell transplantation in pediatric patients with advanced Hodgkin's lymphoma

Petropoulos, D.; Worth, Laura L.; Mullen, Craig A.; Lockhart, Sharon; Choroszy, Mary; Chan, Kawah

doi:10.1038/sj.bmt.1705458

Cited by 9 publications

(10 citation statements)

References 25 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study by Petropoulos et al [52], pediatric patients with Hodgkin's lymphoma were treated with IFN-(type not specified). Headache was reported in patients as part of mild constitutional toxicity, with concomitant fever and chills.…”

Section: Cytokinesmentioning

confidence: 99%

Neurotoxicity of chemotherapeutic and biologic agents in children with cancer

Braganca

Packer²

2008

Curr Neurol Neurosci Rep

View full text Add to dashboard Cite

show abstract

Section: Cytokinesmentioning

confidence: 99%

Neurotoxicity of chemotherapeutic and biologic agents in children with cancer

Braganca

Packer²

2008

Curr Neurol Neurosci Rep

View full text Add to dashboard Cite

show abstract

“…Petropoulos et al 33 described 13 children with 10 of them receiving post-transplant immunotherapy with low-dose IFN-a for up to 24 months. Nine of these patients were alive and in CR with a median follow-up of 67 months.…”

Section: Autologous Hsctmentioning

confidence: 99%

Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma

Claviez

Sureda

Schmitz³

2008

Bone Marrow Transplant

View full text Add to dashboard Cite

Despite the generally excellent prognosis of children and adolescents with Hodgkin's lymphoma (HL), approximately 15% of patients relapse. Salvage therapy options include further chemo-radiotherapy and autologous or allogeneic haematopoietic SCT (HSCT). Autologous HSCT following high-dose chemotherapy, the standard treatment for adult patients with relapsed HL, is also effective in paediatric patients, but randomized trials showing its superiority to conventional therapy are lacking. Although patients with late relapse (412 months after completion of therapy) may be cured with conventional therapy, those with progressive disease or early relapse (3-12 months) are considered candidates for autologous HSCT. According to patient selection criteria, overall and disease-free survival rates after autologous HSCT are 43-95% and 31-70%, respectively. Short time to relapse and refractory disease at the time of autologous HSCT remain the most important risk factors. Data on allogeneic HSCT in children with HL are scarce. Broader use has been hampered for a long time mainly by high non-relapse mortality, offsetting the advantage of a graft-vs-lymphoma effect. Data suggest that young patients with recurring disease following autologous HSCT, as well as some patients with multiple relapses and selected patients with refractory lymphoma, might benefit from allogeneic HSCT, but relapse remains the major challenge.

show abstract

“…[7][8][9][10][11][12][13][14][15][16][17][18][19][20] HDC ASCT is also a common practice in adolescent patients with relapsed or refractory HL but the literature is limited and often a pediatric population is included in the analysis. [21][22][23][24][25][26][27] …”

Section: Introductionmentioning

confidence: 99%